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Summary: The rate of transition from an unstable to a stable complex and the dependence of this on the
number of fatty acid ligands present was determined for the binding of warfarin on human serum albumin.
When oleate or palmitate was added in amounts up to 2:1 excess to human serum albumin Solutions the
measured rate constant for the transition (k2) was increased in comparison with fatty acid free albumin.
When the fatty acid concentration is further increased, k2 decreases. When the fatty acid level is 2 to 3 mol
per mol albumin, the affinity constant (KA) is higher than for fatty acid free Solutions. With higher ratios
the value for KA is reduced.
According to the observed changes in kinetic parameters, the binding of warfarin is apparently affected
allosterically. A reduced plasma protein binding of coumarins should be expected when fatty acid levels are
raised over a prolonged period.
Einfluß von Palmitat und Oleat auf die Bindung von Warfarin an menschliches Serumalbumin: Stopped-Flow
Untersuchungen
Zusammenfassung: Bei der Bindung von Warfarin an Humanserumalbumin wird die Geschwindigkeit der
Umlagerung vom instabilen in den stabilen Warfarin-Humanserumalbuminkomplex von der Anzahl der
Fettsäureliganden bestimmt. Wird Oleat oder Palmitat zu einer Lösung von Humanserumalbumin gegeben,
werden bis zum Überschuß Von 2:1 höhere Werte für die Geschwindigkeitskonstante der Umlagerung (k2)
als bei fettsäurefreiem Humanserumalbumin gemessen. Bei weiterer Erhöhung der Fettsäufekonzentration
| nimmt k2 ab. Auch die Bindüngskönstante (KA) ist abhängig vom Grad der Komplexierung des Humanserum-
J albumins mit den freien Fettsäuren. Bei 2 bis 3 mol Fettsäure pro mol Albumin werden höhere Affmitätskon-
'·· stanten gefunden als in fettsäurefreien Albuminlösungen; bei einem höherem Verhältnis sind die Werte für
KA erniedrigt.
Entsprechend den Änderungen der kinetischen Kenngrößen wird die Warfarinbindung offensichtlich alloste-
' risch beeinflußt. Bei längerfristig erhöhter Fettsäurekonzentration im menschlichen Plasma ist daher eine
verminderte Eiweißbindung für Cumafine anzunehmen.
l
\ ' . free fatty acid undergo specific binding, whereas -
uc on molecules associate unspecifically. Although the
j Human serum albumin has several binding sites for warfarin binding site is located separately, the warfa-
j endogenous and exogenpus substances. The warfarin rin binding process is dependent on the degree of
l binding site (l - 5) and the indole or benzodiazepine Saturation of the albumin molecule by free fatty acids
binding site (2, 4—8) iüteraet specifically with these (16, 22). Thus, a study of the kinetics of the warfarin-
ligands. Other specific binding sites for bilirubin (9, albumin binding process should provide Information
10), digitoxin (4, 11-14) and for long-chain fatty on interaction mechanisms - whether competitive
acids (15-20) have been suggested. According to the or allosteric - between these two dififerent classes of
binding studies by Goodman (21) two molecules of binding sites on albumin.
J. Clin. Chem. Clin. Biochem. / Vol. 23,1985 / No. 11
720 Rictbrock, Mcnke, Reuter, Laßmann and Schmeidl: Influencc of palmitate and oleate on warfarin binding to albumin
Materials and Methods
A solution of fatty acid-free human albumin was prepared by
dissolving crystalline albumin (Sigma, St. Louis, USA) in
double distilled water. The fatty acid content of this solution
using the method of Duncombe (23) was 0.03 m'ol per mol
albumin. The concentration of albumin was determined by UV-
spectroscopy using the absorbance value A2eonm= 5.3 for sol-
utions of 10 g/l albumin in water at pH = 7.4 and T = 298 K.
Solutions used for the measurements were obtained by dilution
with 0.066 mol/1 Sörensen phosphate bufier.
Concentration of warfarin (3-acetonylbenzyl-4-hydroxy-
coumarin) dissolved in Sörensen bufier was determined photo-
metrically using the molar lineic absorbance 8310mm = 1.76 ·
l O3 m2/mol.
Solid sodium palmitate and sodium oleate (Sigma) were dis-
solved in albumin Solutions by stirring and the concentration
determined using the method of Duncombe (23).
Kinetics of warfarin binding were studied in a Durrum-Gibson
stopped-fiow apparatus (22, 24). The complexation reaction
was followed from the time course of fluorescence development.
Excitation energy was generated by a Xenon-high-pressure
lamp (150 Watt) with a maximum at 380 nm. Emission radi-
ation was monitored at 324 nm with sharp cut filtering for
scattered lightof wavelength greaterthan 360 nm. Fluorescence
Signals were displayed on an oscillograph and stored on floppy
discs.
The calculation of kinetic parameters was carried out äs de-
scribed by Rietbrock & Laßmann (24). Two coupled equilibria
are involved in the binding reaction (I):
W + HSA ; * W-HSA'; ^ W-HSA (D
k-2
Association into the primary, unstable complex W-HSA' is fast
and goes to completion in less than 3 ms, which is within the
dead time of the Instrument. Kinetics of this process are thus
too rapid to be studied by stopped-flow measurement. Rear-
rangement into the final stable complex, W-HSA, lasts several
hundred milliseconds and is the rate-limiting Step. The overall
velocity can be characterized by the relaxation constant kre|
(25):
W + cHSA)
^T7=T^k-' (H)
Rearrangement leads to a linear relationship between experim-
ental and calculated constants:
= l
2 k 2 k2 ·
(III)
Results
Effect of variable palmitate concentrations
on the kinetics of warfarin binding on
human serum albumin
The iiifluence of sodium pahnjftate on the rate of
warfarin complexation was studied using a human
serum albumin concentration in the ränge 0.03 · l O"4
mol/1 to 1.09 · 10~4 mol/1 and a warfarin concentra-
tion of 0.025 · 10~4 mol/1 or 0.05 -10~4 mol/1. Typical
fluorescence Signals are shown in figure l, and krei
values, obtained by iterative calculation, are listed in
table l a. Velocity constants k2 (associative process)
and k_2 (dissociative process) cornbined with affinity
constants K^ and KA (tab. 2 a) show evidence for a
relationship between warfarm binding on albumin
and free fatty acid ligandation. Binding velocity is
enhanced by raising the molar concentration ratiö to
2 mol palmitate per mol albumin. Relaxation con-
stants therefore increase, büt on raising the concen-
tration further to more than 3 mol palmitate per mol
albumin, they decrease. The velocity constant k2 is
maximal in the presence of 2 mol free fatty acid per
mol albumin with k2 = 171.6 s"1 in comparison
with 76.9 s"1 for fatty acid-free albumin. With 5 mol
palmitate per mol albumin k2 is 56.0 s"1 (tab. 2 a).
k__2> on the other band, is independent of the degree
of fatty acid ligandation and is approximately 20 s"1
(fig. 2). As a consequence of these findings the bind-
ing constant" KA, 3.6 · l O51/mol (see equation IV), is
affected in a similar manner äs k2 and shows a max-
imum when three mol palmitate are present.
S\A
-100 100 200 300
KA is the affinity constant of the primary complex, c$ and CH§Ä
are concentrations of free warfarin and albumin at equilibrium.
The binding or affinity constant KA for the overall binding
process is obtained by:
(IV)
Fig. 1. The time course of the fluorescence development (380
nrn) of warfarin during complex formation with human
serum albumin at 310 K and pH = 7.4 using excitation
at 324 nm. The concentrations of reactants were: CHSA =
2 · 10-5 mol/l, cw = 5 · IQ-6 mol/1. t1/2 for palmitate/
human serum albumin molar ratlos of (a) l, (b) 2.5 and
(c) 4 were 10 ms, 19 ms and 29 ms, respectively.
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Tab. l. (a) Effect of the molar ratio of palmitate to human
serum albumin (PA/HSA) on the relaxation constant
krd for the binding of warfarin (W) to human serum
albumin at T = 310 K and pH = 7.4.
(b) Effect of the molar ratio of oleate to human serum
albumin (OL/HSA) on the relaxation constant kret for
the binding of warfarin (W) to human serum albumin
atT = 310 K and pH = 7.4.
Tab. l a.
CHSA
(10-4 mol/1)
0.028
0.055
0.092
0.135
0.270
0.540
1.087
cw
0.025
0.025
0.025
0.025
0.025
0.050
0.050
PA/HSA
0:1 1:1
krei(s-')
27 31
28 39
32 52
36 57
45 75
57 87
58 90
2:1
34
39
57
79
113
101
3:1
46
48
63
75
116
127
5:1
21
32
40
47
42
50
Tab. Ib.
CHSA
(10-4 mol/1)
0.028
0.055
0.092
0.135
0.270
cw
0.025
0.025
0.025
0.025
0.025
OL/HSA
0:1 1:1 2:1
kre. (s'1)
27 87 81
28 88 90
32 101 105
36 108 115
45 129 159
3:1
99
87
86
112
127
4:1
71
78
87
81
94
6:1
76
67
68
87
93
Tab. 2. The rate constants (k2, k_2) and affmity constants(KA, KA) for the association and dissociation of warfa-
rin to human serum albumin at 310 K and pH = 7.4
äs a function of:
(a) palmitate concentration;
(b) oleate concentration.
Tab. 2a.
Parameter
;
v
*-2
KA
• 10
5~')
KA
(S-
-4 (1/mol)
• IO-5 (1/mol -s)
')
•io-5 (1/mol)
PA/HSA
0:1
3.1
76.9
24.0
18.0
1.3
1:1
3.3
119.0
39
21
1
.2
.0
.8
2:1
3
171
31
.8
.6
.5
20.0
1.6
3:1
3.5
144.3
49.9
14.0
3.6
5:1
5.4
56.0
30.4
10.0
3.1
. 2b.
Parameter OL/HSA
0:1 1:1 2:1 3:1 4:1 6:1
KA · 10-4 (1/mol) 3.1 5.0 4.8 12.9 20.2 4.5
k2(s-') 76.9 111.3 176.2 112.4 67.3 80.2
k2 · KA · 10-5 (1/mol · s) 24.0 55.7 84.6 145.0 135.9 36.1
k_2 (s-1) 18.0 66.0 50.0 44.0 43.0 49.0
KA · 10-5 (1/mol) 1.3 0.8 1.7 3.3 3.2 0.7
Effect of variable oleate concentrat ions on
the kinetics of warfar in b inding on human
serum albumin
The influence of bound oleate on the binding kinetics
of warfarin was examined using the same methods äs
described previously for palmitate. Albumin con-
centration was varied from 0.03 · l O"4 mol/1 to 0.27
• 10~4 mol/1 and the warfarin concentration was held
constant at 0.025 · 10~4 mol/1. As with palmitate,
there was a significant relationship between the oleate
concentration and the relaxation constant (tab. l b).
k2 was maximal, 176.2 s"1, in the presence of 2 mol
oleate per mol albumin. The velocity constant k_2> äs
before, is relatively constant and a maximal binding
constant occurs with 3 mol oleate per mol albumin
(tab. 2 b). With progressively higher oleate concentra-
tions warfarin binding is inhibited to a limited extent,
äs shown by the relationships between k2, k_2 and
the molar ratio (flg. 2).
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Fig. 2. The dependency of the rate constant k2 (o —o) and k_2(O-o), measured at 310 K and pH = 7.4 on the fatty
acid concentration shown äs molar ratios: CPA/CHSA for
palmitate (CPA), and CQL/CHSA for oieate (COL).
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Discussion
The kinetics of the specific warfarin human serum
albumin binding process is clearly dependent on the
concentration of free fatty acids. The enhancement
of the warfarin interactions at its specific binding site
is evidently caused by an allostefic effect since the
binding sites for the two ligands seem to be located
apart from one another. The rate of rearrangement,
described by the velocity constant k2, is increased
when 2 to 3 mol free fatty acid per mol albumin
occupy their binding sites. According to the kinetic
Parameters the rearrangement from the primary un-
stable complex W-HSA' into the stable complex W-.
HSA appears to be the rate limiting Step (tab. 2 a and
2 b). Presumably warfarin, in its deprotonated form,
is bound to several amino-acid side chains in the
active cleft. Conformational changes in albumin to
produce the stable bound state are facilitated when
the 2 specific fatty acid binding sites are occupied.
This is reflected in the binding constant KA, and a
competitive interaction between the different ligands
can be excluded.
The results obtained for saturated and unsaturated
fatty acids were similar and thus side-chain stereo-
chemistry is not a determinant factor in this phenom-
enon. The affinity constants derived from the kinetic
Parameters agree well with data of Wüding et al. (16)
measured directly using equilibrium dialysis. These
authors obtained maximal values for KA when the
oleate or palmitate to albumin molar ratio was 3.
The extent of this agreement would of course be
dependent on the assumption that the reaction model
on which calculation of kinetic parameters was based
faithfully reflects the events of the binding and inter-
action process. The effects of fatty acids on the rate
constant k2, which are maximal at a molar ratio of
approximately 2, is in accord with the known exist-
ence of 2 binding sites for free fatty acids on human
serum albumin. In contrast, the binding constant KA
is influenced to some extent by variations in KA, the
pre-equilibrium cpnstant. In the results obtained for
the unsaturated fatty acid oleate, but not palmitate,
there also seems to be some relationship between
oleate concentration and unspecific associatioii (tab.
2b). Here different solution properties based on side
chain stereochemistry may come into question.
Apart from two specific binding sites, there are se-
veral unspecific binding locations which exist on albu-
min. Their number however is not exactly known.
Warfarin and fatty acids are also bound simultane-
ously at unspecific sites; When these binding sites are
saturated, competitive displacement or steric hinder-
ance does occur and is reflected in the decrease in
the extent of binding of warfarin on albumin in
the presence of more than 5 mol fatty acid per mol
albumin. Specific binding of other exogenous small
ligands is inhibited.
Warfarin (Coumadin®) was the chosen model ligand
in this stüdy to inyestigate binding properties äs ä
fünction of the fatty acid level at binding site .
Structurally related coumarins include phenprocou-
mon (Marcumar®) and acecoumarol (Sintrön®).
Binding constants for these three dfugs were of the
same order (26) indicating that binding seems to be
maintained essentially by the cpumarin-ring. Thus,
the coiiclusion from our investigation with warfarin
may be extrapolated to phenprocoumon and acecou-
marol.
A decrease or increase of coumarin protein binding
could have an effect on the pharmacological activity
of anticoagulant drugs. Short-term rises in fatty acid
levels however do not influence the Inhibition of
blood clotting because of the long half-life time of
clotting factors (27). On the other band, diseases
producing long-term increases in fatty acid levels,
e. g. diabetes mellitus (28) and hyperthyreosis (29) or
prolonged extended heparin therapy may cause an
unwanted enhancement in drug action, in particular
where hepatic coumarin-clearance remains constant.
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